News

EGFR-TKI Therapy Proves Effective in Previously Untreated Advanced Lung Cancers

03/22/2018

Section Heading

test

Body

The result from the study suggest that EGFR‐TKI therapy is effective in patients with Del‐19+21L858R mutations, Del‐19/21L858R+atypical mutations, and double atypical mutations, but is less effective in patients with a primary drug‐resistant pattern.

Dr Bo Zhang and colleagues concluded that patients with the Del‐19+21L858R mutations may, therefore, benefit more from treatment with first‐generation TKIs.—Janelle Bradley

Tyrosine kinase inhibitor (TKI) treatment is effective in patients with types of epidermal growth factor receptor (EGFR) mutations and advanced lung adenocarcinomas, according to a study published in Cancer (online: March 15, 2018; doi:10.1002/cncr.31329).

Two or more different EGFR mutations can be detected within a single tumor sample. The frequency and efficacy of TKI treatments for patients with advanced lung adenocarcinomas harboring these mutations is unknown.

Bo Zhang, MD, Shanghai Chest Hospital (Shanghai, China), and colleagues screened a total of 16,840 patients diagnosed with advanced lung cancer and EGFR mutations between January 2011 and January 2017. Researchers retrospectively analyzed the effectiveness of TKIs in patients with complex mutations.

Researchers reported that among the 16,840 patients screened for the study, 5,898 tested positive for complex mutations. A total of 187 patients had complex EGFR mutations and 51 of the patients with advanced adenocarcinoma were treated with TKIs as a first-line treatment.

Researchers noted the objective response rates for patients who had Del‐19+21L858R mutations (n = 15), Del‐19/21L858R+atypical mutations (n = 16), double atypical mutations (n = 8), and complex mutations with a primary drug‐resistant pattern (n = 12) were 75.0%, 60.0%, 71.0%, and 8.3%, respectively. The median progression‐free survival times for the groups were 18.2, 9.7, 9.6, and 1.4 months, respectively.

Recent News

FDA Alerts

FDA Approves Zolbetuximab Plus Chemotherapy for Patients With HER2-Negative Gastric/Gastroesophageal Junction Adenocarcinoma With CLDN18.2-Positive Tumors

10/18/2024

Stephanie Holland ;

Based on results from the SPOTLIGHT and GLOW trials, the FDA has approved first-line zolbetuximab plus fluoropyrimidine and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-negative gastric...

Based on results from the...

10/18/2024

Oncology

Conference Coverage

First-Line Abemaciclib Plus Endocrine Therapy Improves Efficacy Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

10/18/2024

Stephanie Holland ;

Results from the phase 2 ABIGAIL trial demonstrated that first-line abemaciclib plus endocrine therapy improves efficacy compared to standard chemotherapy among patients with HR-positive, HER2-negative advanced breast cancer.

Results from the phase 2 ABIGAIL...

10/18/2024

Oncology

FDA Approval

FDA Approves Tumor Treating Fields Wearable Device for Patients With Metastatic Non-Small Cell Lung Cancer

10/17/2024

Allison Casey ;

On October 15, 2024, the FDA granted approval to the Optune Lua, a wearable device that delivers Tumor Treating Fields, for treatment of patients with metastatic non-small cell lung cancer.

On October 15, 2024, the FDA...

10/17/2024

Oncology

News

Treatment With 131L-Apamistamab Before AlloHCT Demonstrates Efficacy, Safety Among Older Patients With R/R AML

10/15/2024

Amber Denham ;

According to phase 3 results from the SIERRA trial, anti-CD45 radioconjugate 131I-apamistamab was well-tolerated and showed a higher durable complete remission rate than standard care among older patients with relapsed/refractory acute...

According to phase 3 results...

10/15/2024

Oncology

FDA Approval

FDA Approves Inavolisib, With Palbociclib and Fulvestrant, for Endocrine-Resistant, PIK3CA-Mutated, HR-Positive, HER2-Negative Advanced Breast Cancer

10/10/2024

Allison Casey ;

The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.

The FDA has approved inavolisib,...

10/10/2024

Oncology

News

Momelotinib Demonstrates Improved Spleen and Symptom Requirements Among Subgroup of Patients With JAK Inhibitor-Naive Myelofibrosis

10/10/2024

Amber Denham ;

Momelotinib was well-tolerated, improved spleen and symptom responses, and reduced transfusion burden among a subgroup of patients with JAK inhibitor-naive myelofibrosis, determined an analysis of the phase 3 SIMPLIFY-1 study.

Momelotinib was well-tolerated,...

10/10/2024

Oncology

News

Nivolumab, Pomalidomide, and Elotuzumab Combination for Patients With R/R Multiple Myeloma

10/10/2024

Amber Denham ;

Nivolumab plus pomalidomide and dexamethasone plus or minus elotuzumab did not demonstrate a clinical benefit compared with pomalidomide and dexamethasone treatment for patients with relapsed/refractory multiple myeloma, according to phase 3...

Nivolumab plus pomalidomide and...

10/10/2024

Oncology

News

Evaluating Long-Term Efficacy and Safety of AlloSCT Among Patients With Peripheral T-Cell Lymphoma

10/10/2024

Amber Denham ;

While allogeneic stem cell transplantation is the preferred treatment for younger, transplant-eligible patients with relapsed/refractory peripheral T-cell lymphoma, it is currently not recommended as part of first-line consolidation,...

While allogeneic stem cell...

10/10/2024

Oncology

News

Neo/Adjuvant Pembrolizumab Significantly Improves Overall Survival for Patients With Early-Stage Triple-Negative Breast Cancer

10/09/2024

Stephanie Holland ;

According to results from the phase 3 KEYNOTE-522 trial, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab significantly improved overall survival among patients with early-stage triple-negative breast cancer.

According to results from the...

10/09/2024

Oncology

Conference Coverage

Optimal Ifinatamab Deruxtecan Dose for Patients With Heavily Pretreated Extensive-Stage Small Cell Lung Cancer

10/09/2024

Stephanie Holland ;

According to interim analysis results from the ongoing phase 2 IDeate-Lung01 trial, 12 mg/kg of ifinatamab deruxtecan is preferable to 8 mg/kg among patients with heavily pretreated extensive-stage small cell lung cancer.

According to interim analysis...

10/09/2024

Oncology